ASCO 2015: Preliminary results of TATTON, a multi-arm Phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 (savolitinib) or selumetinib in EGFR-mutant lung cancer // Chi-Med
News Archive
Previous Article   |   Next Article
Presentations | 1 May 2015

ASCO 2015: Preliminary results of TATTON, a multi-arm Phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 (savolitinib) or selumetinib in EGFR-mutant lung cancer

Please see http://meetinglibrary.asco.org/content/109556

The associated abstract is available at http://meetinglibrary.asco.org/content/148945-156.

Meeting: 2015 ASCO Annual Meeting
Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Sub-category: Signal Transduction
Abstract No: 2509
Poster Board Number: Board #225
Citation: J Clin Oncol 33, 2015 (suppl; abstr 2509)
Author(s): Oxnard G.R., et al.
Date & Time: Saturday 30 May 8:00 AM–11:30 AM

1 Item
Download PDF